Document:

EX-10.36

 Exhibit 10.36 
  

			
		  	 1, Hyangjeong-dong, Hungduk-gu
 Cheongju-si,
Chungbuk, Korea
 Tel: 82-43-718-2535
 Fax: 82-43-718-2004

www.magnachip.com

 October 16, 2013 
 Woungmoo
Lee

 
 Dear Mr. Lee: 

MagnaChip Semiconductor, Ltd. (“MagnaChip”) is pleased to present you with an offer for employment in the position of Korea Sales
(Senior Vice President), reporting to Brent Rowe, Division Director of Worldwide Sales Division. We believe that you have significant potential to make valuable contributions to MagnaChip, and we hope you will find your employment with us a
rewarding experience. 
 You will be based at MagnaChip’s Seoul office, but will be expected to travel as needed within Korea and to
other destinations as the job may require. The expected start date of your employment is November 1, 2013. 
 Your annual salary will
be KRW 230,000,000 per annum. You will be paid in accordance with MagnaChip’s normal payroll practices and your compensation will be subject to payroll deductions and all required withholdings. Annual salary increases will be determined by
MagnaChip in accordance with MagnaChip’s internal policies and procedures. You will be eligible to earn an annual incentive of up to 30% of your base salary. The annual incentive will be based on company performance and attainment of your
management objectives under a plan to be established and approved the Board of Directors of MagnaChip’s parent company (the “Board”). MagnaChip may from time to time in its sole discretion adjust the salary and benefits paid to you
and its other employees in the normal course of operations. 
 Upon approval by the Board of Directors of MagnaChip Semiconductor
Corporation (the “Board”), you will be granted options to purchase 50,000 shares of MagnaChip Semiconductor Corporation (the “Option”) pursuant to the MagnaChip Semiconductor Corporation 2011 Equity Incentive Plan at the exercise
price the fair market value of a common unit on the date of grant at the time you begin your employment. Your option shall become vested and exercisable during three years form the commencement date of your employment in accordance with MagnaChip
Semiconductor Corporation 2011 Equity Incentive Plan. Prior to receiving the Option you must execute an option agreement in the form as approved by the Board. 

			
	 ●  Page
 2
	  	October 13, 2013

  

As an employee of MagnaChip organization, you will be expected to abide by MagnaChip’s rules and regulations and sign and comply with
MagnaChip’s form employment agreement for employees based in Korea that includes confidentiality and non-competition provisions. Your employment relationship with MagnaChip is at-will, although you will
be eligible for severance programs as required by Korean law. You may terminate your employment with MagnaChip at any time and for any reason whatsoever simply by notifying us, although you agree to provide one month’s notice prior to your
resignation. Likewise, MagnaChip may terminate your employment in accordance with Korean law. 
 This letter forms the complete and
exclusive offer of your employment with MagnaChip. No other representative has any authority to modify or enter into an agreement or modification, express or implied, contrary to the foregoing. Any such modification or agreement must be in writing
and signed by Sang Park, CEO, or Sang-Lyun Oh, HR Director, and must clearly and expressly specify an intent to change the at-will nature of your employment. 

We look forward to your participation in the future growth of MagnaChip. Please indicate your acceptance of this offer of employment by
signing in the space below. Please fax or e-mail an executed copy of this letter to me as soon as possible, with the original to follow by mail. 
  

	
	Sincerely,
	  
 MAGNACHIP SEMICONDUCTOR, LTD.

	
	 /s/ Sanglyun Oh

	Sanglyun Oh
	SVP of Human Resources
	MagnaChip Semiconductor, Ltd.

 THIS EMPLOYMENT OFFER IS WHOLLY AGREED AND ACCEPTED BY: 

 

	
	 /s/ Woung Moo Lee

	Woung Moo LeeEX-10.37

 Exhibit 10.37 

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 AMENDMENT NO. 2 TO

 CLINICAL TRIAL AGREEMENT E2112 

BETWEEN 
 ECOG-ACRIN CANCER RESEARCH
GROUP 
 AND SYNDAX PHARMACEUTICALS, INC. 
 This
Amendment No. 2 (the “Amendment” or “Amendment 2”) to Clinical Trial E2112 entered into on March 14, 2014 (the “Agreement”) is entered into as of July 31, 2015 (the “Effective Date”), by and between ECOG-ACRIN
Cancer Research Group, on behalf of itself and its member hospitals, institutions and physicians (the “Group,” “ECOG” or “ECOG-ACRIN”), and Syndax Pharmaceuticals, Inc. (“Company” or “Syndax”). 

WITNESSETH: 
 WHEREAS, pursuant
to the Agreement, the parties agreed to certain terms specified therein for research services related to Group’s performance of the Study; and 

WHEREAS, the parties agree to revise Section 4 of the Agreement as set forth herein. 

NOW, THEREFORE, the parties hereto, intending to be legally bound hereby, agree as follows: 

 

	A.	To Section 4.B, the words “***” are replaced by “***. 

  

	B.	This Amendment constitutes the full understanding of the parties and a complete and exclusive statement of the terms of their agreement with respect to the subject matter described herein, and no terms, conditions,
understanding, or agreement purporting to modify or vary the terms of this Amendment shall be binding unless made in writing and signed by the parties. 

  

	C.	Except to the extent amended herein, all of the terms and conditions of the Agreement remain in full force and effect. 

  

	D.	Capitalized terms herein that are not defined shall have the meaning ascribed to such terms in the Agreement. 

  

	E.	This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which shall be considered one and the same instrument. 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment, as of the Effective Date, by proper persons duly authorized. 

 

									
	ECOG-ACRIN Cancer Research Group	 		 	Syndax Pharmaceuticals, Inc.
			
	 /s/ Robert L. Comis
	 		 	 /s/ John Pallies

	Name:	 	Robert L. Comis, M.D.	 		 	Name:	 	John Pallies
	Title:	 	Group Co-Chair	 		 	Title:	 	Chief Financial Officer

  
 1EX-10.38

 Exhibit 10.38 

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 FIRST AMENDMENT

 This First Amendment (this “First Amendment”), effective as of the 13 day of August, 2015 (“Amendment Effective
Date”), is made by and between MSD International GmbH (“Merck”) and Syndax Pharmaceuticals, Inc. (“Syndax”). 

WHEREAS, Merck and Syndax entered into a Clinical Trial Collaboration and Supply Agreement (for non-small cell cancer study with expansion cohorts in
non-small cell lung cancer and melanoma) effective as of March 27, 2015 (the “Agreement”); and 
 WHEREAS, the Parties
desire to amend the Agreement on the terms and conditions set forth in this First Amendment to, among other things, (a) provide that Merck will supply to Syndax the Merck Compound for Syndax to evaluate the Merck Compound in Syndax’s
internal clinical ***, and (b) revise the Data Sharing and Sample Testing Schedule. 
 NOW, THEREFORE, the Parties hereby agree as
follows: 
  

	1.	Certain Definitions. Unless otherwise defined herein, capitalized terms used in this First Amendment have the meanings assigned to them in the Agreement. 

 

	2.	Amendment to the Agreement. 

  

	 	a.	The following definitions are hereby added to the Agreement: 

 “Amendment Effective
Date” means August 13, 2015. 
 “***” means the pre-clinical studies to be conducted by Syndax as
described in Appendix C. 
  

	 	b.	The definition of Clinical Data in Section 1.9 of the Agreement is hereby deleted in its entirety and replaced with the following language: 

“1.9 “Clinical Data” means all data (including raw data) and results generated under the Study and the ***; excluding,
however, Sample Testing Results.” 
  

	 	c.	A new Section 3.12 is hereby added to the Agreement as follows: 

 “3.12 Following the
Amendment Effective Date, Merck, or an Affiliate of Merck, will provide to Syndax, at *** to Syndax, the quantities of Merck Compound set forth in Appendix C for the sole purpose of conducting the *** (such compound, the “***”).
The *** provided to Syndax pursuant to this Section 3.12 shall not to be used in humans. The *** provided pursuant to this Section 3.12 shall not be used for any purpose other than the ***. Any unused *** or any derivatives

 
analogs, modifications or components thereof shall be returned to Merck or otherwise disposed of in accordance with instructions from Merck promptly upon completion of the *** or upon termination
of the Agreement as set forth in Article 6.” 
  

	 	d.	A new Appendix C is hereby added to the Agreement, which Appendix C is attached to this First Amendment as Schedule 1. 

  

	 	e.	The Data Sharing and Sample Testing Schedule is deleted in its entirety and replaced with the Data Sharing and Sample Testing Schedule attached to this First Amendment as Schedule 2. 

 

	3.	General. Except as specifically modified or amended by this First Amendment, the terms and conditions of the Agreement remain unchanged and in full force and effect. All references in the Agreement to
“Agreement” shall refer to the Agreement as modified by this First Amendment. No provision of this First Amendment may be modified or amended except expressly in a writing signed by both Parties nor shall any terms be waived except
expressly in a writing signed by the Party charged therewith. This First Amendment may be executed in two or more counterparts (facsimile and electronic transmission included), each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument. After facsimile or electronic transmission, the Parties agree to execute and exchange documents with original signatures. 

[signature page follows] 

  
 2 

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 IN WITNESS WHEREOF, the Parties hereto have caused this First Amendment to be executed by their duly authorized
officers or representatives as of the Amendment Effective Date. 
  

			
	MSD International GmbH
		
	By:	 	 ***

	Name:	 	 ***

	Title:	 	 ***

	
	Syndax Pharmaceuticals, Inc.
		
	By:	 	 /s/ John Pallies

	Name:	 	 John Pallies

	Title:	 	 Chief Financial Officer

  
 3 

*** INDICATES MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Schedule 1 to First Amendment 

Appendix C 
 *** 

*** testing in *** 
 *** 

  
 *** INDICATES 1 PAGE OF MATERIAL
THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

 Schedule 2 to First Amendment 

Schedule I 
 DATA SHARING AND
SAMPLE TESTING SCHEDULE 
 *** 

  
 5 

*** INDICATES 2 PAGES OF MATERIAL THAT WAS OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT WAS REQUESTED. ALL SUCH OMITTED MATERIAL WAS FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]